INTRODUCTION {#s1}
============

Pancreatic neuroendocrine tumours (p-NETs) are rare, accounting for \<3% of all pancreatic tumours with an annual incidence of approximately \<1 per 100,000 population \[[@R1]-[@R4]\]. They have shown an increasing prevalence over the past two decades largely due to widespread awareness and advances in diagnostic techniques \[[@R2]-[@R6]\]. P-NETs may produce a variety of hormones, such as insulin, gastrin, glucagon, vasoactive intestinal peptide (VIP), serotonin, somatostatin, adrenocorticotropic hormone (ACTH), etc. and are regarded as functional when hormone overproduction is associated with clinical features of the same \[[@R7]\]. In contrast, p-NETs without corresponding symptoms of hormone overproduction are considered to be non-functional, which may present with abdominal pain, jaundice, weight loss or other non-specific symptoms or may be detected incidentally \[[@R6], [@R8], [@R9]\]. Now, there are no universally accepted definitions of functional and non-functional p-NETs \[[@R3], [@R10], [@R11]\].

Due to their rarity and heterogeneous nature, p-NETs have been poorly defined, and the ability to classify patients with p-NETs into prognostic groups has always been challenging \[[@R6]\]. At present, there are two main Tumour-Node-Metastasis (TNM) systems to stage p-NETs. The European Neuroendocrine Tumour Society (ENETS) staging system \[[@R12]\] was proposed by Rindi et al. in 2006 for gastrointestinal and pancreatic neuroendocrine tumours. The American Joint Committee on Cancer (AJCC) staging system \[[@R13]\] was proposed in 2010 and subsequently endorsed by both the International Union for Cancer Control (UICC) \[[@R14]\] and the World Health Organisation (WHO) \[[@R15]\], which was primarily applied to classify pancreatic exocrine tumours. These two systems differ much in their respective definition of 'T' stage (Table [1](#T1){ref-type="table"}), which results in corresponding differences when staging p-NETs. AJCC stage I disease encompasses all tumours that are confined to the pancreas, whereas ENETS stage I is restricted to tumours confined to the pancreas and \<2cm in diameter; AJCC stage III disease refers to locally advanced tumours involving the superior mesenteric artery or coeliac axis, whereas ENETS stage III includes locally advanced tumours that may be resectable or unresectable \[[@R16]\]. Meanwhile, it is difficult to distinguish T2 and T3 AJCC stages as this requires the identification of peri-pancreatic soft tissue invasion, which is sometimes challenging \[[@R17], [@R18]\].

###### ENETS and AJCC TNM staging systems for p-NETs

  T/N/M       ENETS                                                                                                                                            AJCC
  ----------- ------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------
  T1          Tumour limited to the pancreas, \<2 cm in greatest diameter.                                                                                     Tumour limited to the pancreas, ≤2 cm in greatest diameter.
  T2          Tumour limited to the pancreas, 2-4 cm in greatest diameter.                                                                                     Tumour limited to the pancreas, \>2 cm in greatest diameter.
  T3          Tumour limited to the pancreas, \>4 cm in greatest diameter, or invading duodenum or common bile duct.                                           Tumour extends beyond the pancreas, but not involving the celiac axis or superior mesenteric artery.
  T4          Tumour invades adjacent structures (stomach, spleen, colon or the wall of large vessels including coeliac axis or superior mesenteric artery).   Tumour involves the coeliac axis or superior mesenteric artery (unresectable tumour).
  N0          No regional LN metastasis                                                                                                                        No regional LN metastasis
  N1          Regional LN metastasis                                                                                                                           Regional LN metastasis
  M0          No distant metastasis                                                                                                                            No distant metastasis
  M1          Distant metastasis                                                                                                                               Distant metastasis
  **Stage**                                                                                                                                                    
  Ia          NA                                                                                                                                               T1 N0 M0
  Ib          NA                                                                                                                                               T2 N0 M0
  IIa         NA                                                                                                                                               T3 N0 M0
  IIb         NA                                                                                                                                               T1-3 N1 M0
  III         NA                                                                                                                                               T4 N0-1 M0
  IV          NA                                                                                                                                               Any T M1
  Or                                                                                                                                                           
  I           T1 N0 M0                                                                                                                                         NA
  IIA         T2 N0 M0                                                                                                                                         NA
  IIB         T3 N0 M0                                                                                                                                         NA
  IIIA        T4 N0 M0                                                                                                                                         NA
  IIIB        Any T N1 M0                                                                                                                                      NA
  IV          Any T Any N M1                                                                                                                                   NA

ENETS, European Neuroendocrine Tumour Society; AJCC, American Joint Committee on Cancer; TNM, tumour-node-metastasis; p-NETs, pancreatic neuroendocrine tumour; LN, lymph node; NA, not applicable.

Some studies have validated and compared the 2 TNM staging systems and their ability to prognosticate effectively in terms of the overall survival (OS) of p-NETs \[[@R16], [@R19]-[@R23]\], but few evaluated them for functional or non-functional tumours respectively. In the present study, undertaken at a single specialist centre in China, we investigated the prognostic value of the two TNM systems in patients with p-NETs, as a whole, and more interestingly in functional and non-functional groups separately, with a view to ascertaining any potential clinical benefits of using one system over the other in each of these two sub-groups.

RESULTS {#s2}
=======

Patient demographics and tumour characteristics {#s2_1}
-----------------------------------------------

### All p-NETs {#s2_1_1}

As Table [2](#T2){ref-type="table"} showed, a total of 165 eligible patients were enrolled in our present study. A hundred and ten patients (66.7%) had functional p-NETs, while 55 cases (33.3%) were diagnosed as non-functional. Seventeen patients (10.3%) with asymptomatic non-functional p-NETs were detected incidentally by health examination. All patients underwent pancreatic surgery including 143 patients (86.7%) with radical resections and 22 (13.3%) with palliative or explorative operations. The clinical characteristics of all patients with p-NETs were clearly outlined in Table [3](#T3){ref-type="table"}. Based on the available pathological information of all specimens, the WHO 2010 grading classification was only applied to 114 tumours - there were 62 NET G1, 35 NET G2, and 17 neuroendocrine carcinoma (NEC) G3. Patients had a median follow-up time of 49.7 months and a mean of 52.5 ± 32.5 months (range 5.9 to 135.9), with 41 (24.8%) dead ones.

###### Functional sub-groups and surgical procedures undertaken for all p-NETs

  Variables                              n (%)
  -------------------------------------- -------------
  **Functional status(N=165)**           
   Functional group                       110 (66.7)
    Insulinoma                            99 (60.0)
    Gastrinoma                            5 (3.0)
    VIPoma                                2 (1.2)
    ACTHoma                               2 (1.2)
    Glucagonoma                          1 (0.6)
    Pheochromocytoma                     1 (0.6)
   Non-functional group^\*^              55 (33.3)
    Nausea and vomiting                  33 (60.0)
    Abdominal pain and mass              28 (50.9)
    Health examination                   17 (30.3)
    Jaundice                             9 (14.5)
    Gastrointestinal bleeding            7 (12.1)
    Weight loss                          4 (7.3)
  **Surgical procedure(N=165)**          
   Radical resection                     143 (86.7)
    LP                                   62 (37.6)
    DP                                   42 (25.5)
    PD                                   24 (14.5)
    Others†                              15 (9.1)
   Palliative or explorative operation   22 (13.3)

\*One patient might present two or more clinical manifestations; †Such as central pancreatectomy and total pancreatectomy; p-NETs, pancreatic neuroendocrine tumour; VIPoma, vasoactive intestinal polypeptidoma; ACTHoma, adrenocorticotropic hormone adenoma. LP, local resection of pancreatic tumour (enucleation included); DP, distal pancreatectomy; PD, pancreaticoduodenectomy.

###### Characteristics of functional and non-functional sub-groups of p-NETs

  Variables                        All          Functional   Non-functional   *P*\*
  -------------------------------- ------------ ------------ ---------------- -------
  No. of patients                  n=165        n=110        n=55             
  Gender, n (%)                                                               0.078
   Male                            75 (45.5)    44 (40)      31 (56.4)        
   Female                          90 (54.5)    66 (60)      24 (43.6)        
  Age at diagnosis, yrs, mean±SD   46.6 ±14.2   43.3 ±14.5   52.4 ±11.6       0.021
  Tumour size, cm, mean ± SD       3.0 ± 2.3    2.3 ± 2.4    5.1 ±1.9         0.015
  Tumour location, n (%)                                                      0.126
   Head and/or uncinate            70 (42.4)    42 (38.2)    28 (50.9)        
   Body and/or tail                95 (57.6)    68 (61.8)    27 (49.1)        
  Lymph node invasion, n (%)       20 (12.1)    8 (7.3)      12 (21.8)        0.281
  Distant metastasis, n (%)        16 (9.7)     6 (5.5)      10 (18.2)        0.136
  WHO 2010 grade, n (%)†                                                      0.425
   NET G1                          62 (54.4)    47 (41.2)    15 (13.2)        
   NET G2                          35 (30.7)    8 (7.0)      27 (23.7)        
   NEC G3                          17 (14.9)    7 (6.1)      10 (8.8)         
  Main operations, n (%)‡                                                     0.247
   LP                              62 (48.4)    50 (61.7)    12 (25.5)        
   DP                              42 (32.8)    22 (27.2)    20 (42.6)        
   PD                              24 (18.8)    9 (11.1)     15 (31.9)        
  Dead at follow-up§               41 (24.8)    20 (18.2)    21 (38.2)        0.418
  T stage by ENETS                                                            0.125
   T1                              90           81           9                
   T2                              17           7            10               
   T3                              25           13           12               
   T4                              33           9            24               
  Clinical stage by ENETS                                                     0.351
   I                               78           69           9                
   II                              36           13           23               
   III                             35           22           13               
   IV                              16           6            10               
  T stage by AJCC                                                             0.495
   T1                              90           81           9                
   T2                              37           11           26               
   T3                              23           12           11               
   T4                              15           6            9                
  Clinical stage by AJCC                                                      0.276
   I                               106          86           20               
   II                              32           14           18               
   III                             11           4            7                
   IV                              16           6            10               

\**P* value indicates the comparison between functional and non-functional groups; †Total n=114, functional group n=62, non-functional group n=52; ‡Total n=128, functional group n=81, non-functional group n=47; §Total n=140, functional group n=90, non-functional group n=50; p-NETs, pancreatic neuroendocrine tumours; SD, standard deviation; WHO, World Health Organisation; NEC, neuroendocrine carcinoma; LP, local resection of pancreatic tumour (enucleation included); DP, distal pancreatectomy; PD, pancreaticoduodenectomy.

### Functional vs. non-functional p-NETs {#s2_1_2}

Also in Table [3](#T3){ref-type="table"}, the mean age at diagnosis of patients with functional p-NETs was significantly lower than that of the non-functional group (*P*=0.021). Tumour diameter was notably smaller in the functional group than that of the non-functional group (*P*=0.015). Most functional p-NETs were of NET G1 grade, as compared to non-functional p-NETs which were mainly of NET G2 and NEC G3 grades according to the WHO grading system (47/62 *vs*. 37/52, *P*=0.425).

Stages and OS by ENETS and AJCC {#s2_2}
-------------------------------

### All p-NETs {#s2_2_1}

According to the definitions of both systems (Table [1](#T1){ref-type="table"}), there were 90 patients with T1 tumours, 17 T2, 25 T3 and 33 T4 by the ENETS 2006 system (Table [3](#T3){ref-type="table"}), which corresponded to 78, 36, 35 and 16 cases with stages I to IV disease respectively. As for the AJCC 2010 criteria, there were 90 T1, 37 T2, 23 T3, and 15 T4 tumours, which resulted to 106, 32, 11 and 16 patients from stages I to IV respectively.

The 5-year OS rate of the whole group was 62.4% (Figure [1A](#F1){ref-type="fig"}). Patients with functional p-NETs present a significantly higher OS than those with non-functional ones (*P*=0.001; Figure [1B](#F1){ref-type="fig"}). Using the ENETS staging system for the whole group of p-NETs (Figure [1C](#F1){ref-type="fig"}), OS differences were statistically significant when comparing stage I with stages III and IV (I *vs*. III, *P*=0.030; I *vs*. IV, *P*\<0.001), as well as stage II with stages III and IV (II *vs*. III, *P*=0.048; II *vs*. IV, *P*\<0.001); the differences between stage I and II were not significant (*P*=0.453). ENETS stage III patients had a significantly higher OS than those with stage IV p-NETs (*P*=0.003). As far as the AJCC staging system was applied for all p-NETs (Figure [1D](#F1){ref-type="fig"}), the OS differences between stage I and those in stages III and IV were statistically significant (I *vs*. III, *P*\<0.001; I *vs*. IV, *P*\<0.001); this was also the case comparing those in stage II and stages III and IV (II *vs*. III, *P*\<0.001; II *vs*. IV, *P*\<0.001). There was no difference in OS when comparing stage I with II, or stage III with IV (I *vs*. II, *P*=0.361; III *vs.* IV, *P*=0.601).

![Kaplan--Meier curves of 5-year overall survival for all p-NETs\
: **(A)** all p-NETs, **(B)** functional sub-groups, **(C)** all p-NETs staged using the ENETS system and **(D)** all p-NETs staged using the AJCC system. P-NETs, pancreatic neuroendocrine tumours; ENETS, European Neuroendocrine Tumour Society; AJCC, American Joint Committee on Cancer.](oncotarget-08-82784-g001){#F1}

### Functional vs. non-functional p-NETs {#s2_2_2}

As Table [3](#T3){ref-type="table"} outlined, most functional p-NETs were of T1 stage (N~(ENETS)\ T1~=N~(AJCC)\ T1~=81). Patients with functional p-NETs were mainly grouped in AJCC stages I and II (N~stage\ I~=86, N~stage\ II~=14, respectively), or in ENETS stages I, II and III (N~stage\ I~=69, N~stage\ II~=13, N~stage\ III~=22, respectively). Most non-functional p-NETs were ENETS system T3 and T4 (N~T3~=12, N~T4~=24, respectively), and AJCC system T2 and T3 (N~T2~=26, N~T3~=11, respectively). Non-functional p-NETs were classified as ENETS system stages II and III (N~stage\ II~=23, N~stage\ III~=13, respectively), or as AJCC system stages I and II (N~stage\ I~=20, N~stage\ II~=18, respectively). Patients with Stage IV disease were equal in functional (N~(ENETS)\ stage\ IV~=N~(AJCC)\ stage\ IV~=6) and non-functional groups (N~(ENETS)\ stage\ IV~=N~(AJCC)\ stage\ IV~=10).

When survival analyses of functional tumours were carried out using the ENETS classification (Figure [2A](#F2){ref-type="fig"}), the OS rate differences of patients with functional p-NETs were statistically significant when comparing stage I with stages III and IV (I *vs*. III, *P*\<0.001; I *vs*. IV, *P*\<0.001), as well as stage II and stages III and IV (II *vs*. III, *P*=0.009; II *vs*. IV, *P*\<0.001); differences in OS of stage I with II or stage III with IV were not significantly different (I *vs*. II, *P*=0.409; III *vs*. IV, *P*=0.499). Using the AJCC criteria (Figure [2B](#F2){ref-type="fig"}), only patients with functional tumours in stage I showed a significantly better OS rate than those with stages III and IV tumours (I *vs*. III, *P*\<0.001; I *vs*. IV, *P*\<0.001), while there were no significant differences when comparing patients in stages I and II, stages II and III, stages II and IV and stages III and IV (all *P*\>0.05). Similarly, using the ENETS system to compare patients with non-functional tumours (Figure [2C](#F2){ref-type="fig"}), stages I, II and III had a significantly better survival than those with stage IV tumours (I *vs*. IV, *P*=0.005; II *vs*. IV, *P*\<0.001; III vs. IV, *P*=0.026). However, there were no OS differences when comparing patients in stage I with those in stages II and III, or between those in stages II and III (all *P*\>0.05). Staging non-functional p-NET patients according to the AJCC system (Figure [2D](#F2){ref-type="fig"}), the differences in OS were statistically significant when comparing patients in stage I with those in stages III and IV (I *vs*. III, *P*=0.001; I *vs*. IV, *P*\<0.001), as well as patients in stage II with those in stages III and IV (II *vs*. III, *P*=0.017; II *vs*. IV, *P*\<0.001); whereas patients in stages I and II or stages III and IV did not show any significant differences in OS (*P*\>0.05).

![Kaplan--Meier curves of 5-year overall survival of the 2 functional sub-groups of p-NETs\
**(A)** Functional sub-group staged using the ENETS system, **(B)** functional sub-group staged using the AJCC system, **(C)** non-functional sub-group staged using the ENETS system and **(D)** non-functional sub-group staged using the AJCC system. P-NETs, pancreatic neuroendocrine tumours; ENETS, European Neuroendocrine Tumour Society; AJCC, American Joint Committee on Cancer.](oncotarget-08-82784-g002){#F2}

Analyses of potential prognostic factors {#s2_3}
----------------------------------------

### All p-NETs {#s2_3_1}

For the whole group of p-NETs (Table [4](#T4){ref-type="table"}), patient age, tumour size, hormone status, surgical intent, WHO 2010 grade, stage by both ENETS and AJCC were all significantly associated with the OS of p-NETs on univariate analysis (all *P*\<0.05), while patients gender, tumour location and main operation weren't (all *P*\>0.05). Further multivariate analyses indicated that only surgical intent, WHO 2010 grade, ENETS and AJCC stage were statistically valuable predictors of OS in p-NETs (Table [5](#T5){ref-type="table"}).

###### Univariate analysis of predictors of overall survival in patients with p-NETs

  ------------------------------------------------------------------------------------------------------------
  Variables              All (n=165)    Functional (n=110)   Non-functional (n=55)                     
  ---------------------- -------------- -------------------- ----------------------- ---------- ------ -------
  Gender                                                                                               

   Male                  2.55           0.108                2.48                    0.072      2.13   0.163

   Female                (1.28-5.08)    (0.92-6.69)          (0.74-6.17)                               

  Age, years\*                                                                                         

   \<Median              0.50           0.048                0.64                    0.375      0.53   0.215

   ≥Median               (0.25-1.00)    (0.24-1.72)          (0.19-1.45)                               

  Tumour size, cm\*                                                                                    

   \<Median              0.26           0.012                0.24                    0.008      0.99   0.989

   ≥Median               (0.13-0.53)    (0.08-0.68)          (0.28-3.50)                               

  Tumour location                                                                                      

   \                     0.52           0.065                0.34                    0.039      0.82   0.681
  Head and/or uncinate                                                                                 

   Body and/or tail      (0.26-1.02)    (0.12-0.95)          (0.33-2.08)                               

  Hormone status†                                                                                      

   Functional            1.91           0.032                \-                      \-         \-     \-

   Non-functional        (1.36-2.68)                                                                   

  ENETS clinical stage                                                                                 

   I and II              0.94           0.005                5.30                    \< 0.001   2.40   0.002

   III and IV            (2.61-5.96)    (2.80-10.05)         (1.38-4.17)                               

  AJCC clinical stage                                                                                  

   I and II              0.07           0.014                0.05                    \< 0.001   0.13   0.001

   III and IV            (0.03-0.16)    (0.02-0.17)          (0.04-0.40)                               

  WHO 2010 grade                                                                                       

   NET G1 and G2         0.11           \< 0.001             0.07                    \< 0.001   0.16   0.014

   NEC G3                (0.01-0.16)    (0.01-0.22)          (0.03-0.45)                               

  Surgical intent                                                                                      

   Radical               6.07           \< 0.001             10.91                   \< 0.001   3.74   0.021

   Palliative            (2.41-15.26)   (3.39-35.13)         (1.22-11.52)                              

  Main operation                                                                                       

   LP                    1.20           0.084                0.63                    0.045      0.83   0.105

   DP and PD             (0.25-2.00)    (0.14-1.02)          (0.49-1.73)                               
  ------------------------------------------------------------------------------------------------------------

\*The median value per each group was used for the respective analysis; †Hormone status was only analyzed for all p-NETs; p-NETs, pancreatic neuroendocrine tumours; HR, hazard ratio; CI, confidence interval; ENETS, European Neuroendocrine Tumour Society; AJCC, American Joint Committee on Cancer; WHO, World Health Organisation; NEC, neuroendocrine carcinoma; LP, local resection of pancreatic tumour (enucleation included); DP, distal pancreatectomy; PD, pancreaticoduodenectomy.

###### Multivariate analysis of predictors of overall survival in patients with p-NETs

  ---------------------------------------------------------------------------------------------------------
  Variables              All (n=165)    Functional (n=110)   Non-functional (n=55)                  
  ---------------------- -------------- -------------------- ----------------------- ------- ------ -------
  Age, years\*                                                                                      

   \< Median             1.32           0.413                \-                      \-      \-     \-

   ≥ Median              (0.54-3.84)                                                                

  Tumour size, cm\*                                                                                 

   \< Median             2.18           0.59                 3.14                    0.935   \-     \-

   ≥ Median              (0.37-4.25)    (0.05-8.26)                                                 

  Tumour location                                                                                   

   \                     \-             \-                   1.12                    0.724   \-     \-
  Head and/or uncinate                                                                              

   Body and/or tail      (0.24-5.62)                                                                

  Hormone status†                                                                                   

   Functional            2.43           0.216                \-                      \-      \-     \-

   Non-functional        (0.35-5.48)                                                                

  ENETS clinical stage                                                                              

   I and II              4.41           0.036                5.22                    0.043   6.72   0.021

   III and IV            (3.25-11.25)   (1.14-18.15)         (0.96-15.24)                           

  AJCC clinical stage                                                                               

   I and II              5.24           0.047                7.65                    0.029   9.62   0.016

   III and IV            (1.21-15.25)   (0.06-21.16)         (1.86-11.25)                           

  WHO 2010 grade                                                                                    

  NET G1 and G2          5.24           0.012                6.21                    0.026   5.14   0.036

  NEC G3                 (1.41-25.15)   (0.95-21.32)         (1.27-28.83)                           

  Surgical intent                                                                                   

   Radical               4.15           0.032                4.92                    0.027   3.22   0.035

   Palliative            (3.23-11.33)   (1.62-19.79)         (1.72-13.52)                           

  Main operation                                                                                    

   LP                    \-             \-                   2.20                    0.802   \-     \-

   DP and PD             (0.11-7.17)                                                                
  ---------------------------------------------------------------------------------------------------------

\*The median value per each group was used for respective analysis; †Hormone status was only analyzed for all p-NETs; p-NETs: pancreatic neuroendocrine tumours; HR, hazard ratio; CI, confidence interval; ENETS, European Neuroendocrine Tumour Society; AJCC, American Joint Committee on Cancer; WHO, World Health Organisation; NEC, neuroendocrine carcinoma; LP, local resection of pancreatic tumour (enucleation included); DP, distal pancreatectomy; PD, pancreaticoduodenectomy.

### Functional vs. non-functional p-NETs {#s2_3_2}

Also in Table [4](#T4){ref-type="table"}, the simultaneous univariate analyses for different function-status p-NETs revealed that tumour size and location, and the main operation performed were associated with the OS in the functional group (all *P*\<0.05), but not in non-functional tumours (all *P*\>0.05). We further calculated on multivariate analyses that, for both functional and non-functional p-NETs sub-groups, surgical intent, WHO 2010 grade, ENETS and AJCC stage were also significant prognostic factors (Table [5](#T5){ref-type="table"}).

DISCUSSION {#s3}
==========

TNM staging is a useful instrument for death-risk assessment and patient stratification that may facilitate effective management, if it accurately reflects the biological behavior and natural history of the cancer that it is being applied to \[[@R22]\]. However, currently, presence of these two TNM systems for p-NETs by ENETS and AJCC might have caused clinical confusion in disease stratification and patient management \[[@R17], [@R27]\]. Also, p-NETs are more indolent in their biological behaviors, with a corresponding better OS than pancreatic exocrine tumours \[[@R28], [@R29]\]. Therefore, evidence is essential for the development and application of a uniform TNM staging system for this group of tumours \[[@R30]\]. A comparative study in 2012 by Rindi et al. \[[@R22]\] concluded that although both TNM systems were independent predictors of OS for p-NETs, the ENETS staging system was superior to the AJCC manual, which demonstrated a more accurate predictive ability for each stage. This result has also been reported by some other subsequent studies \[[@R19], [@R20], [@R23]\]. In the present study, as we described before, when investigating all p-NETs, the analyses similarly indicated that the ENETS system could also more effectively discriminate the OS difference between stages III and IV (*P*=0.003) as compared to the AJCC system (*P*=0.601).

Although some previous studies have compared these 2 TNM staging systems for the OS of p-NETs, most of them just combined functional and non-functional tumours as a whole group for analyses when comparing the prognostic value of various staging systems \[[@R16], [@R20]-[@R22]\]. However, the heterogeneity of p-NETs may not permit the effective application of these systems to both functional and non-functional p-NETs \[[@R31]-[@R36]\]. Our present study for the first time evaluated both TNM systems for different function-status p-NETs separately. For functional sub-group of patients, the ENETS system could effectively discriminate OS differences between stage I and stages III and IV or between stage II and stages III and IV, but the AJCC system could only significantly discriminate OS between stage I and stages II and IV. With respect to the non-functional sub-group, the ENETS system could only effectively discriminate the OS differences between stage IV with stages I, II and III, while the AJCC system, on the other hand, could effectively discriminate OS differences between stage I and stages III and IV, as well as those between stage II stages III and IV. These phenomena provided us proofs that the ENETS system might be more practical for patients with functional tumours, while the AJCC system might be more useful when applied to non-functional p-NETs.

Several studies have confirmed the prognostic value of both TNM systems \[[@R16], [@R19]-[@R23]\]. In our study, the Cox Regression proportional hazards model analyses revealed that stage using both ENETS and AJCC systems, surgical intent and WHO 2010 grade were influential predictors of p-NETs with different functional status, which was similarly in accordance with our previous work \[[@R19], [@R37], [@R38]\]. Tumour size and hormone status were not found to be independent predictors of OS for p-NETs, unlike the reports by Halfdanarson et al. \[[@R3]\] and Bilimoria et al. \[[@R39]\]. Tumour size and location, and main operation were demonstrated to be statistically associated with OS of functional tumours on univariate analysis, but not for non-functional p-NETs \[[@R40]\]. Meanwhile, multivariate modeling demonstrated that although both TNM systems were independent predictors of OS, the AJCC 2010 staging manual showed a larger 95% CI for all patients and in the functional sub-group, while the ENETS 2006 staging system showed a larger 95% CI in non-functional tumours, indicative of a relatively imprecise predictive ability. Our demonstrations indicated that it might be more proper to respectively apply different TNM staging system to different functional-status p-NETs.

The highlight of our study was that it was the first attempt, using a large consecutive series of data from a single institution, at separately validating the 2 TNM staging systems in the functional and non-functional sub-groups of p-NETs to determine which one was more suitable in terms of its prognostic performance. While the potential significance of this study was its contribution to investigating the clinical application of the ENETS and AJCC systems in staging functional and non-functional p-NETs and the further development of these staging systems in p-NETs, it had some limitations. The study was retrospective and conducted at a single centre. Further multi-centre, prospective studies were warranted.

In summary, both TNM staging systems (ENETS and AJCC) were significant predictors of OS for patients with p-NETs, irrespective of functional status. The ENETS system have potential advantages when applied to all p-NETs and to the functional sub-group, while the AJCC manual might be more clinically applicable for non-functional p-NETs.

MATERIALS AND METHODS {#s4}
=====================

Patient selection {#s4_1}
-----------------

This research was approved by the local ethics committee of West China Hospital, Sichuan University, in accordance with the general principles of the Helsinki Declaration \[[@R24]\]. Written informed consent was obtained on admission from all patients for their information to be used for research. Electronic or paper-based medical records of consecutive patients, who were all surgically treated and pathologically diagnosed as p-NETs between January 2002 and February 2014, were retrospectively reviewed. Patients, in whom there was only clinical suspicion but no postoperative pathological confirmation of p-NETs, were excluded from this study. Only four patients underwent regular postoperative medical treatment, who were also excluded in our research. Furthermore, five patients with hereditary syndromes, including multiple endocrine neoplasia type I, von Hippel-Lindau syndrome weren't enrolled as well.

Data collection {#s4_2}
---------------

For included patients, demographics, medical history, clinical presentation, preoperative imaging, tumour location and size, histopathologic results (lymph node involvement, vascular invasion, presence of metastasis, immunohistochemical staining, mitotic count or Ki-67 positive index, etc.), surgical procedures undertaken, perioperative outcomes, in-hospital stay, postoperative pathology findings and follow-up data, were all systematically collected using a pre-defined proforma.

Tumour characteristics {#s4_3}
----------------------

Tumours were clinically classified as functional p-NETs when patients presented typical and specific clinical manifestations related to hormone over-production: insulinoma (typical Whipple triad), gastrinoma (refractory peptic ulcer, diarrhoea, esophagitis), VIPoma (intractable diarrhoea, hypokalaemia), ACTHoma (Cushing syndrome), glucagonoma (migratory erythema, hyperglycaemia), etc. For patients who didn't present typical clinical features related to hormone over-production were considered having non-functional p-NETs, regardless of the immunohistochemical staining of tumour specimens and laboratory evidence of hormone rise \[[@R25]\]. All groups were classified and analysed according to the 2 TNM staging systems by ENETS and AJCC. The 2010 WHO pathological grading system \[[@R26]\] was also applied wherever possible.

Follow-up and survival {#s4_4}
----------------------

Follow-up was conducted mainly by telephone or outpatient clinic appointments. OS was calculated as the number of months from the date of operation to the date of last contact or time of death.

Statistical analysis {#s4_5}
--------------------

All statistical analyses were performed using IBM SPSS 19.0 statistical software. Quantitative variables were reported as mean with standard deviation (SD) and compared using the Student's t or the analysis of variance tests. Categorical variables were presented as numbers with their frequencies as proportions (%) and analysed using Chi-square test (or Fisher's exact test). OS estimates and curves of relevant cases were generated and plotted using the Kaplan-Meier method and then compared using the log-rank test. Univariate and multivariate analyses were applied to explore possible prognostic factors in both functional and non-functional p-NETs, using the Cox Regression proportional hazards model. Hazard ratio (HR) with 95% confidence interval (CI) was calculated for each variable. A *P* value of less than 0.05 was considered to be statistically significant.
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P-NETs

:   pancreatic neuroendocrine tumours

VIP

:   vasoactive intestinal peptide

ACTH

:   adrenocorticotropic hormone

TNM

:   tumour-node-metastasis

ENETS

:   European Neuroendocrine Tumour Society

AJCC

:   American Joint Committee on Cancer

UICC

:   International Union for Cancer Control

WHO

:   World Health Organisation

NEC

:   neuroendocrine carcinoma

OS

:   overall survival

SD

:   standard deviation

HR

:   hazard ratio

CI

:   confidence interval
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